我父亲肺鳞癌的治疗贴(2014年3月1日驾鹤西去）

Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
. k$ g* f4 r0 Y# W5 {NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
+ Author Affiliations
: |) f  M$ I  U" J# c: M$ i5 E
- \& @2 Y7 N7 H. ], s1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
" z; [7 X( l7 S$ ^/ O4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
/ Q" h& q' b6 a! [5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan
" o: }( _7 h3 F' P8 O; |* s7Kinki University School of Medicine, Osaka 589-8511, Japan
; J( O4 |' z9 b- I8Izumi Municipal Hospital, Osaka 594-0071, Japan
+ C2 r- Y% E- v5 f& v# e9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp
# L; s0 T7 r3 _- _* \AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
' V1 U6 @" M6 z( v
" O& O0 V; Y8 ]# {. g! g- l

S-1 monotherapy for previously treated non-small cell lung cancer: A retrospective analysis by age and histopathological type

Authors: Yuki Tomita, Tetsuya Oguri, Osamu Takakuwa, Makoto Nakao, Eiji Kunii, Takehiro  Uemura, Hiroaki Ozasa, Mikinori Miyazaki, Ken Maeno, Shigeki Sato
+ ~% u, F8 Y; f% r  X" U! \6 {
Affiliations: Department of Medical Oncology and Immunology, Nagoya City University Graduate School of Medical Sciences, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601, Japan  

+ k6 R+ i$ t; D) M3 MPublished online on: Thursday, December 1, 2011

: B6 _( `% m0 a. `! TDoi: 10.3892/ol.2011.507
8 o4 e2 X' y- ^- u) F
Pages: 405-410
" T+ D7 }& b+ H- b( j
' z. U# l) E" ^& B! `3 W0 sAbstract:
7 {' ]: x/ Y, f) P' E: v8 ^+ U7 E- I4 NS-1, an oral fluoropyrimidine derivative, has been approved for the treatment of non-small cell lung cancer (NSCLC) in Japan. In the present study, the efficacy and safety of S-1 monotherapy for elderly patients with previously treated NSCLC were retrospectively evaluated, and the efficacy of S-1 monotherapy was compared by histopathological type. This retrospective study included 54 patients with advanced or recurrent NSCLC who had received S-1 monotherapy following the failure of previous chemotherapy regimens at our institutes. Patient outcomes were compared based on their age and histopathological type. S-1 was administered orally, twice daily, while the duration and interval were modified according to the medical condition of each patient. The default delivery schedule, the mean number of S-1 cycles, did not differ significantly between the two age groups (<70 and ≥70 years). The rate of therapy discontinuation, schedule modification or dose reduction due to intolerable toxicities or patient refusal was relatively frequent in the older group (40.7 and 55.6% for ages <70 and ≥70 years, respectively; p=0.414), and the incidence of grade 3 anemia was relatively high in the older group (3.7 and 18.5%, respectively; p=0.192). The response rates (13.0 and 4.8%, respectively; p=0.609) and disease control rates (39.1 and 33.3%, respectively; p=0.761) did not differ significantly between the two age groups. According to histopathological type, the disease control rate was significantly higher in adenocarcinoma (57.9%) compared to non-adenocarcinoma (20.0%, p=0.013). Thus, S-1 monotherapy may be equally effective and tolerated in patients <70 years and those ≥70 years. Additionally, adenocarcinoma may have a higher disease control rate than non-adenocarcinoma.
0 A2 m5 S5 r: d

Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population
) w0 F* S# S! E, W) `7 _F. Tanaka1,*, H. Wada2, Y. Fukui3 and M. Fukushima3
$ ]) B' u: S6 A3 \; u+ Author Affiliations
; c0 }% |1 I" x* t5 h: J" P' M) U1Second Department of Surgery, University of Environmental and Occupational Health, Kitakakyushu
. t# s: C' l% r0 z& a2Department of Thoracic Surgery, Kyoto University, Kyoto
3Tokushima Research Center, Taiho Pharmaceutical Co. Ltd, Tokushima, Japan
8 U9 k6 F1 V) X5 u! E5 L&#8629;*Correspondence to: Dr F. Tanaka, Second Department of Surgery, University of Environmental and Occupational Health, 1-1 Isegaoka, Yahata-nishi, Kitakakyushu, 807-8555, Japan. Tel: +81-93-891-7442; Fax: +81-93-692-4004; E-mail: ftanaka@med.uoeh-u.ac.jp
4 L- K3 Y$ r9 [7 t! k0 hReceived September 3, 2010.
8 i4 V: @  S0 _2 Y# ~3 O+ ^+ X, URevision received November 11, 2010.
Accepted November 17, 2010.
Abstract
Background: Previous small-sized studies showed lower thymidylate synthase (TS) expression in adenocarcinoma of the lung, which may explain higher antitumor activity of TS-inhibiting agents such as pemetrexed.
. `7 z  e, x2 r$ i7 CPatients and methods: To quantitatively measure TS gene expression in a large-scale Japanese population (n = 2621) with primary lung cancer, laser-captured microdissected sections were cut from primary tumors, surrounding normal lung tissues and involved nodes.
Results: TS gene expression level in primary tumor was significantly higher than that in normal lung tissue (mean TS/β-actin, 3.4 and 1.0, respectively; P < 0.01), and TS gene expression level was further higher in involved node (mean TS/β-actin, 7.7; P < 0.01). Analyses of TS gene expression levels in primary tumor according to histologic cell type revealed that small-cell carcinoma showed highest TS expression (mean TS/β-actin, 13.8) and that squamous cell carcinoma showed higher TS expression as compared with adenocarcinoma (mean TS/β-actin, 4.3 and 2.3, respectively; P < 0.01); TS gene expression was significantly increased along with a decrease in the grade of tumor cell differentiation. There was no significant difference in TS gene expression according to any other patient characteristics including tumor progression.
Conclusion: Lower TS expression in adenocarcinoma of the lung was confirmed in a large-scale study.

一直关注老马的帖子，前方的指明灯。祝福你爸好疗效

一直得到老马帮助，祝福老马爸爸

26日吃了12片地米（0.75mg一片），27日吃了22片地米（0.75mg 一片），28日吃了12片地米（0.75mg一片），都分二次吃。
- z/ L% u5 S" v9 Z% S) L今天为止没有任何反应，每天吃VC,VB2，还有漱口水，就怕口腔溃疡。

副作用如何，单药反应很小吧？

LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy
http://clinicaltrials.gov/ct2/show/NCT01523587
0 V% S5 e8 v4 m, i7 U9 m  }9 J
9 B* k9 l* H4 V* y# S& [! FBIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC
: B, M4 \+ x9 i& i" Fhttp://clinicaltrials.gov/ct2/show/NCT01156545

  r5 N* s3 c% D) Y7 o) D$ [
7 K9 ]" h: I4 W* O; ~1 `从4月24日开始到4月28日，打了5天的舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
  }- N: k& ]$ M% f4 x) v至今为止，未出现化疗副作用。

老马 发表于 2012-4-29 20:53

4 [; J( _8 ^% L, w2 f4 @                               
登录/注册后可看大图

从4月24日开始到4月28日，打了5天的打了5天舒普深(注射用头孢哌酮钠舒巴坦钠),效果非常好。
) u/ I" @/ ?0 X( r, k' ?) I6 n至今为止，未出 ...

没有副作用是第一追求，效果显著是第二追求。
不错。